Under the harvest, pharmaceutical companies face quality and cost challenges, how can fish and bear palms have both?

Pharmaceutical Network Market Analysis: Under the background of the national consistent evaluation policy of collecting and generic drugs, most pharmaceutical companies are facing the difficult problems of quality and cost.
, how do fish and bear palms have both? Drug companies face quality and cost challenges under the collection, how do fish and bear palms have both? (Source: Pharmaceutical Network) Under the background of the quality and cost challenges faced by pharmaceutical companies in the context of in-depth policies such as national volume procurement and generic drug consistency evaluation, the pharmaceutical industry urgently needs to accelerate transformation and upgrading, and pharmaceutical companies face quality and cost challenges.
, consistent evaluation has become the basic entry threshold for generic drugs to obtain national collection qualification.
the impact of the policy's continuous promotion, pharmaceutical companies in order to enhance competitiveness, its quality awareness continues to improve, the entire industry is facing the pressure of transformation and upgrading and quality efficiency.
other hand, with the normalization of collection, the variety of drugs continues to expand, will have a profound impact on the development of pharmaceutical enterprises and the entire pharmaceutical industry.
the situation of inflated drug prices will be reconstructed.
drug companies, in order to retain or expand their market share, by changing stocks at low prices while subjecting them to stricter regulation.
But in the long run, once the drug company varieties into the collection, because do not have to worry about product sales problems, save a lot of marketing costs, and with the product volume, the future sales contribution rate will be improved, for enterprises, especially many small and medium-sized pharmaceutical companies, is undoubtedly a corner over the opportunity.
therefore, for pharmaceutical companies, the current need to consider and solve the problem of low prices and quality.
do you have both "fish" and "bear's paw"? In the industry's view, drugs as a special commodity, related to the health of patients, so at least four characteristics need to be met, namely, safe, effective, accessable, quality control.
, the quality and safety of medicines can be seen as a lifeline for pharmaceutical companies and cannot be exceeded.
if companies sacrifice the quality and safety of their drugs to reduce costs, they will have to face high illegal costs under the strict supervision of the current pharmaceutical industry.
", it is understood that in accordance with the new version of the Drug Administration Law, the lower limit of the sale of counterfeit drugs a fine of 1.5 million, retail drug sales of the lower limit of 100,000.
, in the context of the normalization of mining, drug prices have become a trend, enterprises in the low price war, also need to rely on quality to survive.
, how to ensure the quality of medicines? The industry says improving drug traceability is key.
drug traceability system refers to trace and track all drug information, which is conducive to promoting the supervision of drug quality and safety, preventing the occurrence of drug quality and safety accidents, and ensuring the safety of patients' drug use.
recent years, relevant policies have also identified this aspect.
, for example, in 2019 issued the "Drug Information Trace System Construction Guide", "Drug Trace Code Code Requirements", put forward the requirements to speed up the construction of drug traceability system.
According to the plan, the drug traceability system should cover the production, circulation and use of various links, with information means to ensure the quality of drug production and operation of safety, to prevent counterfeit drugs, inferior drugs into legal channels, and can achieve drug risk control, to ensure that the requirements traceable.
, the newly amended Drug Administration Act also requires holders to establish and implement a retrospective system to ensure the traceability of medicines.
at the same time, in particular, will establish and improve the drug traceability system, in order to achieve "one thing one yard, one yard with the pursuit" as the direction.
that enterprises to improve drug traceability of specific measures can include: the adoption of international coding standards, the construction of drug traceability service platform, adhere to the production, circulation and other industry-wide drug traceability.
The State Drug Administration has been building a retrospective coordination platform, traceability regulatory platform, and will issue a series of traceability of technical standards, to bring more commercial value to pharmaceutical companies, but also conducive to further ensure that the drug traceability to achieve the full variety, the whole process of sources can be traced, to traceable.
cost control, reducing sales costs has become one of the means of cost savings for many pharmaceutical companies.
this year, the pharmaceutical industry layoffs and pay cuts, the removal of sales teams, high-level adjustments, restructuring adjustments, etc. are in turn.
, especially some of the performance of enterprises affected by the collection, most pharmaceutical companies are inclined to save costs first, take the initiative to change their own development model.
in the industry's view, under the current environment, pharmaceutical companies also need to do a good job of fine management, further cost savings, while accelerating transformation and innovation.
.